Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks
Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. An early look at the phase 1b/2a data showed amyloid levels fell below a disease threshold in 81% of patients after 28 weeks.
Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. An early look at the phase 1b/2a data showed amyloid levels fell below a disease threshold in 81% of patients after 28 weeks.
